Working paper: Incentivizing progress, even if small and incremental, in therapies for Alzheimer’s disease should be a priority
Martha Deja and Marc Herant
October 22, 2024
Summary: Over the coming decades, Alzheimer’s disease threatens to become a huge drag on national well-being. To put things in perspective, by 2040, the US may be allocating more resources to the care of Alzheimer’s patients than care and education of children. Unfortunately, we are not likely to find a therapeutic “silver bullet”; progress will most probably take place in incremental steps as is the case with the latest A-beta directed therapies. Because of the potential modest benefit of new individual therapies, one could reasonably argue to place stringent limits